Aspiriant Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Aspiriant reduced its stake in Abbott Laboratories by 3.68% during the most recent quarter end. The investment management company now holds a total of 52,133 shares of Abbott Laboratories which is valued at $2,348,592 after selling 1,994 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Abbott Laboratories makes up approximately 0.20% of Aspiriant’s portfolio.

Other Hedge Funds, Including , Dimensional Fund Advisors Lp boosted its stake in ABT in the latest quarter, The investment management firm added 814,053 additional shares and now holds a total of 3,465,752 shares of Abbott Laboratories which is valued at $156,028,155. Abbott Laboratories makes up approx 0.09% of Dimensional Fund Advisors Lp’s portfolio.Pzena Investment Management boosted its stake in ABT in the latest quarter, The investment management firm added 685,278 additional shares and now holds a total of 5,327,448 shares of Abbott Laboratories which is valued at $241,120,296. Abbott Laboratories makes up approx 1.42% of Pzena Investment Management’s portfolio.Coho Partners Ltd. boosted its stake in ABT in the latest quarter, The investment management firm added 162,703 additional shares and now holds a total of 1,883,333 shares of Abbott Laboratories which is valued at $85,239,652. Abbott Laboratories makes up approx 3.02% of Coho Partners Ltd.’s portfolio.Flossbach Von Storch Ag boosted its stake in ABT in the latest quarter, The investment management firm added 4,936,655 additional shares and now holds a total of 14,514,773 shares of Abbott Laboratories which is valued at $649,536,092. Abbott Laboratories makes up approx 10.71% of Flossbach Von Storch Ag’s portfolio.Middleton Co Incma reduced its stake in ABT by selling 227 shares or 0.35% in the most recent quarter. The Hedge Fund company now holds 64,429 shares of ABT which is valued at $2,781,400. Abbott Laboratories makes up approx 0.62% of Middleton Co Incma’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $44.68 with 86,30,316 shares getting traded on Wednesday. Post opening the session at $45.14, the shares hit an intraday low of $44.44 and an intraday high of $45.14 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *